The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000825358p
Ethics application status
Help: Ethics application status
Submitted, not yet approved
Date submitted
Help: Date submitted
29/05/2026
Date registered
Help: Date registered
9/07/2026
Date last updated
Help: Date last updated
9/07/2026
Date data sharing statement initially provided
Help: Data sharing statement date
9/07/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Can infrared laser light therapy safely reduce chronic pelvic pain in women with endometriosis?
Scientific title
A single-arm feasibility and dose-escalation study of dorsal root ganglion-targeted photobiomodulation for endometriosis-associated persistent pelvic pain
Additional trial identifiers [1] 317423 0
Nil known
Universal Trial Number (UTN)
Trial acronym
PBM for PPP
Related trial records

Health condition
Health condition(s) studied:
Endometriosis-associated persistent pelvic pain 342094 0
Persistent pelvic pain 342095 0
Endometriosis 342096 0
Chronic pain 342097 0
Condition category
Condition code
Reproductive Health and Childbirth 338213 338213 0 0
Other reproductive health and childbirth disorders
Anaesthesiology 338214 338214 0 0
Pain management
Physical Medicine / Rehabilitation 338215 338215 0 0
Physiotherapy

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Participants will receive photobiomodulation (PBM) therapy delivered using infrared laser light targeting the dorsal root ganglia (T10–L1 and S2–S4) associated with pelvic innervation. The intervention is applied transcutaneously over paraspinal and sacral regions corresponding to the targeted neural structures.

PBM is delivered using a SYMBYX ProSeries device with a three-diode 808 nm probe operating in pulsed mode. Each diode delivers an average output power of 400 mW. Pulse frequency will be standardised prior to study commencement. Treatment is administered by a trained physiotherapist following a standardised protocol. Participants receive up to 12 treatment sessions over an 8-week period. The intervention will be delivered individually within a clinical research environment.

Laser energy is applied to 12 predefined treatment sites. Dose is expressed as energy density (J/cm²), with dwell time per site determined by the target fluence. Total PBM delivery time varies according to dose. The starting baseline dose is 3.5 J/cm². Total session duration is up to approximately 30 minutes, including setup, positioning, and safety procedures.

A structured dose-escalation framework is used. For the first participant, treatment begins at 3.5 J/cm² (6 seconds dwell time per site) and increases in fixed increments of 3.5 J/cm² per session to a maximum dose of 21 J/cm² (33 seconds dwell time per site), over the first six sessions unless escalation is withheld due to predefined safety or response criteria. The dose is then maintained at this level for the remaining sessions.

For subsequent participants, the starting dose is derived from the preceding participant’s Session 7 dose (reference dose). This dose is maintained for the first six sessions (latency-hold phase) to allow delayed and cumulative biological responses to emerge. From Session 7 onward, dose escalation may occur in increments of 3.5 J/cm², with up to six escalation opportunities, guided by inter-session pain-response criteria and tolerability rules defined in the protocol.

All dose-escalation decisions, delivered doses, and session parameters are recorded in the study database. Intervention adherence and safety are monitored throughout the study, including documentation of adverse events and participant-reported responses.
Intervention code [1] 334222 0
Treatment: Other
Intervention code [2] 334618 0
Treatment: Devices
Description of the comparator or control
No control group
Control group
Uncontrolled

Outcomes
Primary outcome [1] 345588 0
Feasibility of study processes (assessed as a composite outcome), including recruitment, consent, retention, study completion, and adherence to the planned intervention schedule
Timepoint [1] 345588 0
Assessed throughout the study period, including the 8-week intervention phase and at end of main study (16 weeks)
Primary outcome [2] 345591 0
Acceptability and tolerability of the intervention (assessed as a composite outcome)
Timepoint [2] 345591 0
Assessed at each treatment session during the 8-week intervention phase and at end of main study (16 weeks)
Primary outcome [3] 345592 0
Safety (assessed as a composite outcome), including incidence, nature, and severity of adverse events (AEs), adverse reactions (ARs), and tolerability-limiting events (TLEs)
Timepoint [3] 345592 0
Assessed continuously throughout the study period, including during the 8-week intervention and at end of main study (16 weeks)
Secondary outcome [1] 462287 0
Pelvic pain intensity
Timepoint [1] 462287 0
NPRS daily during the 8-week intervention period, with BPI measures collected weekly throughout the study (Week 1-16) and at the 6-month timepoint
Secondary outcome [2] 462297 0
Spatial distribution of pain
Timepoint [2] 462297 0
Basline and end of main study period (week 16)
Secondary outcome [3] 462298 0
Analgesic use and self-management (assessed as a composite outcome)
Timepoint [3] 462298 0
Weekly across the study period, until end of main study period (week 16)
Secondary outcome [4] 462299 0
Quality of life and endometriosis impact (assessed as a composite outcome)
Timepoint [4] 462299 0
Weeks 4 (end of run-in phase), 8 and 12 (during intervention), 16 (post-intervention). 6 months (follow-up): EHP-30 only
Secondary outcome [5] 462300 0
Outcome measure feasibility (assessed as a composite outcome), including completeness, variability, and interpretability of candidate outcome measures
Timepoint [5] 462300 0
Throughout the study period, including end of main study (16 weeks) and 6-month follow-up
Secondary outcome [6] 462302 0
Durability of change – Sustained changes in pain and patient-reported outcomes at follow-up
Timepoint [6] 462302 0
6-month follow-up
Secondary outcome [7] 463791 0
Pain interference
Timepoint [7] 463791 0
Weekly assessment points from Week 1 to Week 16, and at the 6-month timepoint.

Eligibility
Key inclusion criteria
Individuals assigned female at birth aged 18–39 years
Confirmed endometriosis (imaging or histopathology)
Persistent pelvic pain of 3 months or greater, localised to pelvic/lumbopelvic region
Pain consistent with segmental/central sensitisation, defined by:
– Convergences Pelvic Pain Score (CPPS) score of 5 or greater
– Fibromyalgia Patient Self-Report Survey (FM Survey) score of 1–11
Preserved but hormonally regulated ovarian function (not fully suppressed)
Stable hormonal regimen
Body Mass Index (BMI) 18–30 kg/m²
Fitzpatrick skin type I–III
Able to provide consent and comply with study procedures
Minimum age
18 Years
Maximum age
39 Years
Sex
Females
Healthy volunteers
No
Key exclusion criteria
Pregnancy or breastfeeding
Absent, suppressed, or unregulated ovarian function (e.g. menopause, GnRH therapy, natural cycling without regulation)
Pain profile inconsistent with pelvic sensitisation (CPPS score of less than 5; FM Survey score of 12 or greater)
Clinically significant PTSD or neurodevelopmental conditions affecting sensory processing (e.g. ADHD, ASD)
Unstable medical or psychiatric illness
Contraindications to PBM (e.g. implanted devices, photosensitivity, impaired sensation at treatment sites)
Recent pelvic pathology (infection, significant bleeding, or surgery within 3 months)
Active malignancy or serious systemic disease
BMI outside 18–30 kg/m² or Fitzpatrick IV–VI
Inability to comply with study procedures or provide informed consent

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Not Applicable
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis
Analyses will be primarily descriptive and feasibility-focused, summarising recruitment, retention, adherence, data completeness, and adverse events.

Exploratory analyses will examine changes in pain, function, and quality of life over time.
Continuous variables will be summarised using means ± SD or medians (IQR); categorical variables using counts and percentages.

No formal hypothesis testing or efficacy inference will be undertaken; analyses are descriptive and hypothesis-generating only.

Findings will inform dose selection, outcome measures, and sample size estimation for a subsequent randomized controlled trial.

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
QLD
Recruitment hospital [1] 29556 0
Mater Hospital Brisbane - South Brisbane
Recruitment postcode(s) [1] 45879 0
4101 - South Brisbane

Funding & Sponsors
Funding source category [1] 321997 0
Charities/Societies/Foundations
Name [1] 321997 0
Betty McGrath Grant, Mater Foundation
Country [1] 321997 0
Australia
Primary sponsor type
Charities/Societies/Foundations
Name
Mater Research Institute
Address
Country
Australia
Secondary sponsor category [1] 324873 0
University
Name [1] 324873 0
University of Queensland
Address [1] 324873 0
Country [1] 324873 0
Australia

Ethics approval
Ethics application status
Submitted, not yet approved
Ethics committee name [1] 320531 0
Mater Misericordiae Ltd Human Research Ethics Committee
Ethics committee address [1] 320531 0
Ethics committee country [1] 320531 0
Australia
Date submitted for ethics approval [1] 320531 0
06/05/2026
Approval date [1] 320531 0
Ethics approval number [1] 320531 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 150774 0
A/Prof Liisa Laakso
Address 150774 0
Mater Research | Level 2 | Aubigny Place | South Brisbane | Queensland | 4101
Country 150774 0
Australia
Phone 150774 0
+61 419 686 134
Fax 150774 0
Email 150774 0
Contact person for public queries
Name 150775 0
Matthew Hunt
Address 150775 0
Mater Research | Level 2 | Aubigny Place | South Brisbane | Queensland | 4101
Country 150775 0
Australia
Phone 150775 0
+61 7 3163 7897
Fax 150775 0
Email 150775 0
Contact person for scientific queries
Name 150776 0
Matthew Hunt
Address 150776 0
Mater Research | Level 2 | Aubigny Place | South Brisbane | Queensland | 4101
Country 150776 0
Australia
Phone 150776 0
+61 7 3163 7897
Fax 150776 0
Email 150776 0

Data sharing statement
Will the study consider sharing individual participant data?
No
No IPD sharing reason/comment: No plans to make individual participant data publicly available



What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.